• Hinova Pharma

  Participated · Series C · Oct 2020

  Hinova Pharmaceuticals, founded in 2013 and based in Chengdu, discovers, develops, and industrialises drugs targeting metabolic diseases and cancers. Its pipeline includes nine drug candidates, notably HC-1119, an innovative androgen receptor antagonist for metastatic castration-resistant prostate cancer (mCRPC) now in Phase III international multi-centre trials. The company expects HC-1119 to reach the global market in 2022. Hinova said the new financing will support multi-centre clinical trials and the commercialization of its drug candidates domestically and internationally. The firm is also recruiting a chief financial officer with preferred expertise in city board biomedical listings and Hong Kong IPO experience. To date it has completed prior financings including a Series B+ in January 2020 that raised US$32 million from six institutional investors including GF Xinde Investment.

• ESR

  Participated · Equity · Jan 2017

  e-Shang Redwood is a pan-Asia logistics real estate developer and operator that focuses on institutional-quality warehouses across major gateway markets in Asia. The company was formed by a January 2016 merger of e-Shang and Redwood. It currently has 6.5 million square meters of projects in operation or under development in China, Japan and South Korea, with another over 6 million square meters in the pipeline. e-Shang was initially founded in 2011 by Warburg Pincus with Jeffrey Shen and Dongping Sun; Redwood was founded in 2006 by Charles de Portes and Stuart Gibson. The firm has been a leading third-party landlord for major e-commerce companies in China and South Korea. It recently secured a significant pre-IPO equity investment to support its operations and growth pipeline.

No current team members are available.